[Skip to Content]
[Skip to Content Landing]
March 5, 1997

Aspirin's Role in Prevention Now Official

JAMA. 1997;277(9):701-702. doi:10.1001/jama.1997.03540330025010

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


ASPIRIN is about to get broader official recognition as a useful agent in the prevention of heart attack and stroke. But it will be no news to those physicians who have been prescribing aspirin for their patients at risk of cardiovascular disease.

Meeting jointly, 2 Food and Drug Administration (FDA) advisory committees, Cardio-Renal Drugs and Nonprescription Drugs, have recommended to the FDA commissioner that he approve the use of aspirin as a preventive measure in patients who are at high risk for cardiovascular disease but do not have a history of a myocardial infarction (MI) or have stable angina. Aspirin is currently recommended to reduce the risk of death or a nonfatal MI only in patients with a previous history of MI or in those with unstable angina.

"When it's approved, it will be a major addition to the claims structure for aspirin. There are a lot of people with